Russia’s Sputnik vaccine received its first approval in the European Union, United Arab Emirates


A medical worker fills a syringe with gum-kovid-vaccine (under the brand name of Sputnik V) in Butovo, South Moscow.

Sergey Savostyanov | TASS | Getty Images

DUBAI, United Arab Emirates – Russia’s Sputnik v Kovid-19 vaccine received a series of promotions on Thursday to Hungary and the United Arab Emirates, becoming the first country in the European Union and the Gulf region to register shots for emergency use, respectively Gone.

Hungary’s decision was confirmed by a spokesman for President Viktor Orbán, who said that if the country agreed to a shipment agreement with Moscow, it would become the first European Union country to receive the vaccine. This comes as the country’s cases have fallen from a peak of over 6,000 per day in early December to below 2,000 per day.

“This decision is very important because it shows that the safety and efficacy of over 90% of the vaccine is highly regarded by our partners in Hungary,” Kirill Dimryk, head of the Russian Direct Investment Fund, said in a statement.

The EU drug regulator is yet to approve the Russian jab, although German Chancellor Angela Merkel on Thursday gave Sputnik hopeful, suggesting that Germany’s vaccine regulator Russia should navigate the EU approval process Can advise RDIF has filed Sputnik for EU registration and is expected to be reviewed in February.

UAE approval comes amid dramatic increase in infections

The approval from the United Arab Emirates comes amid a record increase in cases in the small Gulf Sheikhomed, which stands out internationally to welcome tourists and fully reopen its economy in the summer of last year.

Confirmed coronavirus cases have increased more than threefold over a three-week span, just days after Emirati authorities assured “control of the virus” in hospitals and surgical surgeries due to “recreational activities” in hospitals Suspected surgery stopped.

The UAE’s daily case count on Thursday was a record 3,529, far more than its neighboring Gulf Arab countries, where infections were recorded below 500 per day.

An Emirati man, wearing a protective mask, walks into the Al-Barsa Health Center in the Gulf Emirates of Dubai on December 24, 2020.

GIUSEPPE CACACE | Via AFP Getty Image

Sputnik V will be the third vaccine to be deployed in the UAE after the Sinopharm vaccine in China and was made available to the US and German-developed Pfizer-Bayonet Tech in December. The nation of about 10 million is saying that its government says that Israel is the second fastest national vaccination campaign in the world after per capita and intends to vaccinate half the country’s residents by the end of March.

The country’s health ministry said in a statement on Thursday about Sputnik’s approval, “This decision comes as part of the UAE’s comprehensive and integrated efforts to ensure the level of prevention.” “The results of the study have demonstrated a strong antibody response against the virus, its safety for use, and the effectiveness of the vaccine for compliance with international safety and effectiveness standards.”

Lack of late-stage trial data

Approval came despite detailed research data not yet published on the results of the Phase 3 human trial of the vaccine. UAE capital Abu Dhabi started Phase 3 trials for Sputnik V earlier this month, but has not released data on them. The RDIF states that 1,000 volunteers in the Emirates received their first dose.

Sputnik V, which its developer, Gamalaya Research Institute, says is 91% effective after two doses, has been in use throughout Russia for months. Scientists have expressed concern over what many have described as a congested rollout of the vaccine, a green light for widespread use in Russia before the completion of Phase 3 trials.

As the first phase of the largest vaccination campaign in Argentina’s history, first-line health workers are receiving the Russian Sputnik V vaccine against coronovirus.

Patricio Murphy | SOPA Images | Lighterket | Getty Images

Analysis of the vaccine’s Phase 1 and 2 trials was published in September in the peer-reviewed medical journal The Lancet, which said the initial results showed no major negative side effects, but that more studies were needed. .

According to Sputnik V’s official website, “Results of Phase III clinical trials are expected to be published soon.”

Prior to Thursday’s announcements, it was approved for use in 9 countries and regions outside Russia – Algeria, Argentina, Bolivia, Belarus, Serbia, Venezuela, Paraguay, Turkmenistan and the Palestinian Territory.

.

Leave a Reply

Your email address will not be published.